Is AOD-9604 Legal in Massachusetts? How to Access It Legally

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide fragment. Specifically, it corresponds to amino acids 177 to 191 of human growth hormone (hGH), with a tyrosine residue added at the N-terminus. The fragment was originally isolated by researchers at Monash University in Australia who hypothesized that this region of the hGH molecule drives lipolysis without the insulin-sensitizing or IGF-1-elevating effects of full-length growth hormone [1].

Mechanism of Action

The peptide binds beta-3 adrenergic receptors in adipose tissue and may stimulate fat oxidation through a pathway that does not require IGF-1 elevation [2]. Because it lacks the full hGH receptor-binding domain, proponents argue it avoids the diabetogenic and proliferative risks associated with recombinant hGH. That argument has not been confirmed in large randomized controlled trials.

What the Clinical Record Shows

Metabolica Pharmaceuticals (later Calzada, formerly Metabolic Pharmaceuticals) conducted a series of trials under the brand name AOD9604. The Phase IIb trial registered as NCT00356291 enrolled 299 adults with obesity and tested four oral doses over 12 weeks [3]. Subjects receiving 1 mg daily lost approximately 2.6 kg versus 1.3 kg in the placebo arm, a difference that was statistically significant but clinically modest. No Phase III trial was completed. The FDA never granted approval. Oral bioavailability data remain limited, and injectable formulations used in current compounding practice differ substantially from the oral form studied in that trial [4].

The Federal Legal Framework for AOD-9604

AOD-9604 is not an FDA-approved drug. That single fact drives every downstream legal question, including access in Massachusetts.

The Drug Approval Gap

Because AOD-9604 has no approved New Drug Application (NDA) and no Biologics License Application (BLA), it cannot be marketed commercially in the United States as a finished pharmaceutical product [5]. Prescribing an unapproved substance is not automatically illegal for a licensed physician under federal law, but manufacturing, selling, or distributing it without complying with either the Federal Food, Drug, and Cosmetic Act (FDCA) or the compounding exemptions creates significant legal exposure [6].

Section 503A: The Individual Compounding Pathway

Section 503A of the FDCA, codified at 21 USC 503A, allows state-licensed pharmacies to compound drugs for individual patients when a valid prescription exists [7]. A bulk drug substance may be used in 503A compounding only if it meets one of three criteria:

• It appears on the FDA's 503A bulks list as a substance that may be used in compounding (Category 1).
• It is a component of an FDA-approved drug.
• It was used in compounding before 1997 and has not been withdrawn for safety or effectiveness reasons.

AOD-9604 does not appear on the FDA's affirmative Category 1 bulks list. The FDA's 2023 interim final rule and prior proposed rules placed numerous peptides under evaluation [8]. Substances not yet affirmatively listed occupy an uncertain zone: they are neither clearly permitted nor always actively enforced against, but compounding them carries regulatory risk that individual pharmacies assess differently.

Section 503B: Outsourcing Facilities

Section 503B outsourcing facilities can produce larger batches of compounded drugs for healthcare providers without patient-specific prescriptions, but only using substances on the 503B-specific bulks list or approved drug components [9]. AOD-9604 is not on the 503B bulks list. An outsourcing facility that compounds AOD-9604 for office stock would be operating outside the 503B safe harbor.

The FDA's Peptide Crackdown: 2023 to 2025

Beginning in 2023, the FDA signaled increased scrutiny of injectable peptides sold through compounding channels. The agency issued guidance clarifying that bulk drug substances nominated for the 503A list but not yet evaluated, or evaluated and placed in a category that restricts use, cannot be freely compounded [10]. Several peptides, including BPC-157 and TB-500 (thymosin beta-4), were named explicitly. AOD-9604 has not received an identical named enforcement letter as of the date of this article's last review, but it falls within the broader category of unapproved peptides subject to the same statutory analysis.

Clinicians and patients seeking AOD-9604 should verify current FDA guidance directly at fda.gov before initiating therapy, because this regulatory area moves quickly.

Massachusetts State Law: What It Does and Does Not Prohibit

Massachusetts has no statute that names AOD-9604 or bans it as a controlled substance. The state's Controlled Substances Act mirrors the federal Schedules I through V under Massachusetts General Laws Chapter 94C [11]. AOD-9604 is not scheduled at the federal or state level. That absence of a specific prohibition does not create a positive legal right to obtain or prescribe it, however.

The Massachusetts Board of Registration in Pharmacy

The Massachusetts Board of Registration in Pharmacy (BORP) licenses and regulates pharmacies in the state, including compounding pharmacies. The BORP requires that compounding comply with United States Pharmacopeia (USP) standards, including USP Chapter 795 for nonsterile and USP Chapter 797 for sterile preparations [12]. Because AOD-9604 is typically compounded as a sterile injectable, any Massachusetts pharmacy compounding it must meet USP 797 standards for environmental monitoring, personnel training, and beyond-use dating.

The Medical Practice Act and Prescriber Liability

Massachusetts physicians, nurse practitioners, and physician assistants operate under the Massachusetts Medical Practice Act and their respective licensing boards. Prescribing an unapproved substance is not categorically prohibited under state law, but prescribers carry responsibility for justifying clinical decisions with evidence and for obtaining adequate informed consent [13]. A prescriber who recommends AOD-9604 should document the rationale, disclose the absence of FDA approval, and note the limited Phase II evidence.

No State-Level Exemption Exists

Some practitioners assume that because Massachusetts has no specific prohibition, AOD-9604 is simply legal in the state. That reading is incomplete. Federal law still governs the supply chain. A Massachusetts compounding pharmacy filling an AOD-9604 prescription is subject to FDA oversight. Operating outside the 503A framework exposes the pharmacy to FDA warning letters, injunctions, and potential criminal liability under the FDCA [14].

How to Access AOD-9604 Legally in Massachusetts

Legal access requires three things working together: a qualified prescriber, a compliant pharmacy, and a valid patient-specific prescription.

Step 1: Establish Care with a Licensed Prescriber

A physician, nurse practitioner, or physician assistant licensed in Massachusetts must evaluate your clinical situation before writing a prescription. Telehealth is permitted in Massachusetts for established patients under the state's telehealth parity law. The prescriber should have documented familiarity with peptide therapy, compounding regulations, and the current FDA status of AOD-9604 [15].

No legitimate prescriber will write an AOD-9604 script without a clinical encounter. Avoid any source that sells the peptide without requiring a prescription.

Step 2: Obtain the Prescription from a 503A-Compliant Pharmacy

The prescription must go to a state-licensed 503A compounding pharmacy. The pharmacy must:

• Hold a valid Massachusetts BORP license.
• Comply with USP 797 for sterile compounding.
• Source the bulk AOD-9604 from an FDA-registered active pharmaceutical ingredient (API) supplier.
• Dispense only to the individual named patient, not as an office-stock product [16].

Ask the pharmacy directly whether they have a certificate of analysis (CoA) for the bulk AOD-9604 and whether the API supplier is FDA-registered. A reputable pharmacy will provide both on request.

Step 3: Understand What You Are Agreeing To

Before starting therapy, a patient should understand three things. First, AOD-9604 is not FDA-approved for any indication, including fat loss or body composition improvement. Second, the longest published controlled trial lasted 12 weeks with oral dosing; long-term safety data for injectable AOD-9604 are not available from completed randomized trials [17]. Third, the regulatory status may change. If the FDA formally places AOD-9604 in a restricted category on the 503A bulks list, compounding pharmacies in Massachusetts would be required to stop dispensing it.

Dosing Context from Published Research

The Phase IIb oral trial used doses ranging from 1 mg to 10 mg daily [3]. Injectable protocols used in compounding practice typically cite 300 mcg subcutaneously per day, five days per week, based on extrapolation from preclinical data and the hGH fragment's pharmacokinetic profile. No published randomized trial has validated that injectable dose or schedule in humans [18]. Patients and prescribers should treat injectable dosing as investigational.

Red Flags: What to Avoid

Several channels sell AOD-9604 as a "research chemical" with labels stating "not for human use." Purchasing from these sources carries legal and safety risks. The label "not for human use" does not protect buyers or sellers from FDCA liability when the product is clearly intended for human administration [19]. These products are not manufactured under current Good Manufacturing Practice (cGMP) standards, meaning sterility, potency, and purity cannot be verified.

Buying AOD-9604 from offshore websites or domestic gray-market suppliers bypasses every protection that the compounding pharmacy framework provides. The FDA has issued warning letters to multiple companies selling peptides under research-chemical designations while marketing them for human use [20].

What Prescribers in Massachusetts Should Know

Prescribers who consider recommending AOD-9604 should review the FDA's current position on the 503A bulks list before prescribing. The Endocrine Society's clinical practice guideline on growth hormone use in adults does not endorse AOD-9604 or any hGH fragment peptide for fat loss [21]. The absence of an endorsement from a major specialty society is relevant context for informed consent.

Documentation Requirements

Prescribers should maintain a chart note that includes the patient's clinical indication, a summary of the available evidence (including the Phase IIb trial result), the lack of FDA approval, and the patient's acknowledgment of these limitations. Massachusetts malpractice exposure for prescribing unapproved substances follows general negligence standards: the question would be whether a reasonable clinician with similar training would make the same decision given the available evidence [13].

Monitoring Recommendations

No validated monitoring protocol exists specifically for AOD-9604. Reasonable precautions drawn from the hGH fragment's pharmacology include baseline and periodic fasting glucose, insulin, IGF-1, and lipid panels. If IGF-1 rises above the age-adjusted normal range, the prescriber should evaluate whether the peptide is causing off-target hGH receptor activity. The 2021 Endocrine Society guideline on growth hormone in adults defines normal IGF-1 ranges by age and sex and provides a reasonable reference point [22].

The 503A Bulks List: Current Status and What Could Change

The FDA's process for evaluating bulk drug substances for 503A compounding involves a public nomination process, internal review, and publication in the Federal Register. The FDA has published proposed rules identifying substances that may and may not be used in 503A compounding. As of early 2025, AOD-9604 has not been placed in the affirmative "Category 1" list of substances that may be compounded [8].

The FDA's November 2023 final rule on bulk drug substances used in compounding under 503A (88 FR 77860) provides the most current definitive federal statement on which peptides have cleared the evaluation process. AOD-9604 is not among those cleared. Compounding it remains legally uncertain rather than clearly permitted.

If the FDA moves AOD-9604 to the negative list (Category 2, substances that may not be compounded), Massachusetts pharmacies would be required to stop immediately. Patients currently on AOD-9604 therapy should be aware that therapy could be interrupted by a federal regulatory decision that is outside anyone's control at the state level.

Comparing AOD-9604 to Approved Alternatives

Patients seeking fat-loss or body-composition support have access to several FDA-approved options that carry none of the legal ambiguity surrounding AOD-9604.

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo in STEP-1 (N=1,961, P<0.0001) [23]. Tirzepatide 15 mg (Zepbound) produced 20.9% mean weight loss at 72 weeks versus 3.1% placebo in SURMOUNT-1 (N=2,539, P<0.001) [24]. Both drugs carry FDA approval for chronic weight management, full prescribing information, and post-marketing safety surveillance data covering hundreds of thousands of patients.

AOD-9604's Phase IIb result of approximately 2.6 kg over 12 weeks compares unfavorably on both effect size and evidence quality. Patients and prescribers should weigh that comparison directly when making treatment decisions.